Incidence of venous thromboembolic (VTE) in chronic lymphocytic leukemia (CLL) patients (pts) treated with immunomodulating agents (IMiDs)

8625 Introduction: We recently reported the clinical activity of IMiDs (both thalidomide (T) and lenalidomide (L)) in pts with CLL. VTE is a commonly reported complication of these agents requiring prophylaxis. Most available information is in pts treated for multiple myeloma (MM), a disease with a high baseline incidence of VTE. To determine whether the incidence of IMiDs associated VTE is similar in CLL pts we reviewed all CLL pts treated with IMiDs at our institute. Method: All CLL pts treated at our institute with T or L either alone or in combination with other antileukemic agents such as rituximab (R) or fludarabine (F)) were evaluable for this analysis. All pts were treated on IRB approved clinical trials and signed informed consent. Prophylaxis for VTE was recorded. Dose range for T was 100–300mg/day, while that of L was 5–25mg/day. Results: To date a total of 55 pts (35 on L and 20 on T) are treated with IMiDs at our center. All pts treated with L received single agent L while those treated with ...